Antisense Oligonucleotides Therapeutics Is Fastest Growing Segment Fueling The Growth Of Antisense Oligonucleotides Market
Market Overview:
Antisense oligonucleotides are short segments of synthetic nucleic acid sequences that are used to target messenger RNA (mRNA) in the human body. They help in down-regulating gene expression by binding to complementary mRNA sequences through Watson-Crick base pairing, thereby preventing translation into targeted proteins. Antisense oligonucleotides find applications in the treatment of various genetic disorders including Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA).
Market key trends:
One of the major trends in the antisense oligonucleotides market is the growing use of RNA interference (RNAi) technology for drug development. RNAi technology utilizes short interfering RNAs (siRNAs) and microRNAs (miRNAs) to silence target genes implicated in diseases. This technology helps achieve sequence-specific silencing of target genes without affecting the expression of other genes. Companies operating in the market are increasingly investing in RNAi technology-based drug candidates to expand their product pipelines. Another trend gaining attention is the growing focus on developing antisense oligonucleotides for neurological disorders treatment including Alzheimer’s disease, amyotrophic lateral sclerosis, and Huntington’s disease.\
The global Antisense Oligonucleotides Market Share is estimated to be valued at US$ 2,913.5 Mn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The global antisense oligonucleotides market is segmented based on type, indication, and region. By type, the market is segmented into RNA interference (RNAi), and ribozymes. The RNA interference (RNAi) segment is expected to dominate the global market during the forecast period. RNAi uses small interfering RNAs (siRNAs) or microRNAs (miRNAs) to destroy and inhibit target messenger RNAs (mRNAs) before they are translated into proteins. This makes it a very effective antisense therapy for a wide range of diseases.
Key Takeaways
The global antisense oligonucleotides market is expected to witness high growth, exhibiting CAGR of 6.6% over the forecast period, due to increasing investments in research and development of novel antisense drugs and a rising global prevalence of chronic diseases like cancer and cardiovascular diseases.
Regional analysis related content comprises
The North America region dominates the global antisense oligonucleotides market and is expected to continue its dominance over the forecast period. This is attributed to increasing research funding, rising prevalence of genetic disorders and cancer, presence of major players, and advancements in oligonucleotide drug development in the region.
Key players related content comprises
Key players operating in the antisense oligonucleotides market are Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences. Ionis Pharmaceuticals currently dominates the market with its flagship product SPINRAZA, the first approved drug for spinal muscular atrophy.